Literature DB >> 22815558

Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II.

Michelle M Mielke1, Veera Vankata Ratnam Bandaru, Norman J Haughey, Jin Xia, Linda P Fried, Sevil Yasar, Marilyn Albert, Vijay Varma, Greg Harris, Eric B Schneider, Peter V Rabins, Karen Bandeen-Roche, Constantine G Lyketsos, Michelle C Carlson.   

Abstract

OBJECTIVES: Previous studies have shown that high serum ceramides are associated with memory impairment and hippocampal volume loss, but have not examined dementia as an outcome. The aim of this study was to examine whether serum ceramides and sphingomyelins (SM) were associated with an increased risk of all-cause dementia and Alzheimer disease (AD).
METHODS: Participants included 99 women without dementia aged 70-79, with baseline serum SM and ceramides, enrolled in a longitudinal population-based study and followed for up to 6 visits over 9 years. Baseline lipids, in tertiles, were examined in relation to all-cause dementia and AD using discrete time Cox proportional survival analysis. Lipids were analyzed using electrospray ionization tandem mass spectrometry.
RESULTS: Twenty-seven (27.3%) of the 99 women developed incident dementia. Of these, 18 (66.7%) were diagnosed with probable AD. Higher baseline serum ceramides, but not SM, were associated with an increased risk of AD; these relationships were stronger than with all-cause dementia. Compared to the lowest tertile, the middle and highest tertiles of ceramide d18:1-C16:0 were associated with a 10-fold (95% confidence interval [CI] 1.2-85.1) and 7.6-fold increased risk of AD (95% CI 0.9-62.1), respectively. The highest tertiles of ceramide d18:1-C24:0 (hazard ratio [HR] = 5.1, 95% CI 1.1-23.6) and lactosylceramide (HR = 9.8, 95% CI 1.2-80.1) were also associated with risk of AD. Total and high-density lipoprotein cholesterol and triglycerides were not associated with dementia or AD.
CONCLUSIONS: Results from this preliminary study suggest that particular species of serum ceramides are associated with incident AD and warrant continued examination in larger studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22815558      PMCID: PMC3414665          DOI: 10.1212/WNL.0b013e318264e380

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

1.  Alzheimer peptides perturb lipid-regulating enzymes.

Authors:  Mark P Mattson; Roy G Cutler; Dong-Gyu Jo
Journal:  Nat Cell Biol       Date:  2005-11       Impact factor: 28.824

2.  Amyloid beta oligomerization is induced by brain lipid rafts.

Authors:  Sang-Il Kim; Jae-Sung Yi; Young-Gyu Ko
Journal:  J Cell Biochem       Date:  2006-10-15       Impact factor: 4.429

3.  Ganglioside G(M1)-mediated amyloid-beta fibrillogenesis and membrane disruption.

Authors:  Eva Y Chi; Shelli L Frey; Ka Yee C Lee
Journal:  Biochemistry       Date:  2007-01-26       Impact factor: 3.162

4.  ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain.

Authors:  Veera Venkata Ratnam Bandaru; Juan Troncoso; David Wheeler; Olga Pletnikova; Jessica Wang; Kathy Conant; Norman J Haughey
Journal:  Neurobiol Aging       Date:  2007-09-20       Impact factor: 4.673

5.  Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin.

Authors:  Marcus O W Grimm; Heike S Grimm; Andreas J Pätzold; Eva G Zinser; Riikka Halonen; Marco Duering; Jakob A Tschäpe; Bart De Strooper; Ulrike Müller; Jie Shen; Tobias Hartmann
Journal:  Nat Cell Biol       Date:  2005-11       Impact factor: 28.824

6.  Serum sphingomyelins and ceramides are early predictors of memory impairment.

Authors:  Michelle M Mielke; Veera Venkata Ratnam Bandaru; Norman J Haughey; Peter V Rabins; Constantine G Lyketsos; Michelle C Carlson
Journal:  Neurobiol Aging       Date:  2008-05-05       Impact factor: 4.673

7.  Frequency and course of mild cognitive impairment in a multiethnic community.

Authors:  Jennifer J Manly; Ming-X Tang; Nicole Schupf; Yaakov Stern; Jean-Paul G Vonsattel; Richard Mayeux
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

8.  Lipid membrane templates the ordering and induces the fibrillogenesis of Alzheimer's disease amyloid-beta peptide.

Authors:  Eva Y Chi; Canay Ege; Amy Winans; Jaroslaw Majewski; Guohui Wu; Kristian Kjaer; Ka Yee C Lee
Journal:  Proteins       Date:  2008-07

9.  Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?

Authors:  Pavel Katsel; Celeste Li; Vahram Haroutunian
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

10.  Association of ceramides in human plasma with risk factors of atherosclerosis.

Authors:  Ikuyo Ichi; Kayoko Nakahara; Yayoi Miyashita; Atsuko Hidaka; Sahoko Kutsukake; Kana Inoue; Taro Maruyama; Yoshikazu Miwa; Mariko Harada-Shiba; Motoo Tsushima; Shosuke Kojo
Journal:  Lipids       Date:  2006-09       Impact factor: 1.646

View more
  82 in total

Review 1.  HDL-cholesterol and apolipoproteins in relation to dementia.

Authors:  Manja Koch; Majken K Jensen
Journal:  Curr Opin Lipidol       Date:  2016-02       Impact factor: 4.776

2.  The 5XFAD Mouse Model of Alzheimer's Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden.

Authors:  Michael B Dinkins; Somsankar Dasgupta; Guanghu Wang; Gu Zhu; Qian He; Ji Na Kong; Erhard Bieberich
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 3.  Sphingolipids and lifespan regulation.

Authors:  Xinhe Huang; Bradley R Withers; Robert C Dickson
Journal:  Biochim Biophys Acta       Date:  2013-08-15

4.  Alzheimer disease: blood-based biomarkers in AD--a silver lining on the horizon.

Authors:  Christoph Laske
Journal:  Nat Rev Neurol       Date:  2012-08-14       Impact factor: 42.937

5.  Markedly perturbed hematopoiesis in acid ceramidase deficient mice.

Authors:  Shaalee Dworski; Alexandra Berger; Caren Furlonger; Joshua M Moreau; Makoto Yoshimitsu; Jessa Trentadue; Bryan C Y Au; Christopher J Paige; Jeffrey A Medin
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

6.  A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise.

Authors:  Mahwesh Saleem; Nathan Herrmann; Adam Dinoff; Michelle M Mielke; Paul I Oh; Prathiba Shammi; Xingshan Cao; Swarajya Lakshmi Vattem Venkata; Norman J Haughey; Krista L Lanctôt
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 7.  Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.

Authors:  Marcus O W Grimm; Daniel M Michaelson; Tobias Hartmann
Journal:  J Lipid Res       Date:  2017-05-20       Impact factor: 5.922

8.  Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia.

Authors:  Shashwath A Meda; Gualberto Ruaño; Andreas Windemuth; Kasey O'Neil; Clifton Berwise; Sabra M Dunn; Leah E Boccaccio; Balaji Narayanan; Mohan Kocherla; Emma Sprooten; Matcheri S Keshavan; Carol A Tamminga; John A Sweeney; Brett A Clementz; Vince D Calhoun; Godfrey D Pearlson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

Review 9.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

Review 10.  Sphingolipids in neurodegeneration (with focus on ceramide and S1P).

Authors:  Guanghu Wang; Erhard Bieberich
Journal:  Adv Biol Regul       Date:  2018-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.